Европейская академия естественных наук Hannover E.V.

Ma, George Xiao-Bo

Dr. George Xiao-bo Ma is currently the Chairman of Xiamen Danguikang Biotech Co., Ltd. He formerly served as a senior executive at Apotex Inc., the largest pharmaceutical company in Canada, for 14 years, as well as a senior executive at renowned listed companies such as Hengrui Pharmaceuticals and Huahai Pharmaceuticals in China; He also founded Natureme Inc., a Canadian company and served as its president; Dr. Ma is an internationally renowned pharmaceutical expert who has developed over 30 prescription medicines, and created an efficacy-based formulation technology. The natural Peijia series health products developed using this technology have solved multiple health problems in the fields of cardiovascular, cerebrovascular, pulmonary respiration, and anti-cancer, and is an important supplement to hospital therapy, filling the gap in this field. This project was rated as an excellent project with funding by Ministry of Human Resources and Social Security of China in 2022. Dr. Ma graduated from the Institute of Chemistry of the Chinese Academy of Sciences with Ph.D. degree in organic/drug synthesis; He engaged in postdoctoral research at the University of California (Irvine) in the United States and the University of Toronto in Canada; He has won the world-renowned Humboldt Research Award in Germany and served as a Humboldt Researcher for nearly three years; In 2011, Dr. Ma wrote and edited the 700000-word book "US ANDA New Requirements and Case Studies" published with the support of the China Food and Drug Administration, which became an important textbook and reference book; In 2013, he collaborated to write the relevant chapters of Volume 38 of the American Pharmaceutical Professional Series, "Profiles of Drug Substances, Excipients, and Related Methodology". As a visiting professor at the State Food and Drug Administration Institute of Executive Development, Dr. Ma came to China to give advanced lectures on drug research and development from Canada every year for nearly 10 years, cultivating a large number of pharmaceutical talents, leading Chinese pharmaceutical companies to go abroad, and ushering in a new era of applying for US FDA and European EMA drug approvals; He was elected as one of the expert members of the Peptide Branch Expert Committee of the China Biopharmaceutical Industry Association and an expert member of the Fujian Province New Overseas Chinese Talent Association. In 2020, he was also rated as a leading entrepreneurial and innovative talent introduced from overseas in Fujian Province and a high-level talent introduced from overseas in Xiamen City. Selected as one of the top ten leaders in China brand influence (biotechnology industry) in 2023.

 

вверх

Энциклопедия ЕАЕН

 ¦  Impressum  ¦  Контакт